RE:RE:RE:RE:RE:RE:RE:“Low dose docetaxel”I highlighted the part about consideration of looking for suitable clinical trials as the prognosis of remaining options can't be promising!
"Metastatic castration-resistant prostate cancer (updated 09/2022)
If the cancer is no longer stopped by low testosterone levels (less than 50 ng/mL) and has spread to other parts of the body, it is called “metastatic castration-resistant prostate cancer.” Castration-resistant prostate cancer is defined by a rising PSA level and/or worsening symptoms and/or growing cancer verified by scans. ASCO recommends PSA testing every 3 months for metastatic castration-resistant prostate cancer. Generally, imaging tests, such as CT scan and bone scan, are done to check the growth and spread of cancer and to see how well treatment is working.
Metastatic castration-resistant prostate cancer can be difficult to treat. ASCO recommends continuing treatment that lowers hormone levels for metastatic castration-resistant prostate cancer. ASCO has treatment recommendations for hormone therapy for advanced cancer and for systemic treatment of metastatic castration-resistant prostate cancer.
Treatment options for metastatic castration-resistant prostate cancer are listed below. Treatment in a clinical trial may also be an option.
-
AR inhibitors, such as abiraterone or enzalutamide
-
Targeted therapy with olaparib or rucaparib
-
Chemotherapy with docetaxel, especially if there is bone pain or other cancer-related symptoms
-
Chemotherapy with cabazitaxel if docetaxel stops working
-
Immunotherapy with sipuleucel-T
-
Radioligand therapy (targeted radiation therapy by infusion) using 177Lu-PSMA-617
-
Radium-223, a form of radiopharmaceutical therapy (non-targeted radiation therapy by infusion)
-
Bone-modifying drugs to treat cancer that has spread to the bone"